VRDN · Viridian Therapeutics, Inc.\DE · Debt

On May 11, 2026, Viridian Therapeutics, Inc. (the “Company”) completed its public offering (the “Convertible Notes Offering”) of $250,000,000 aggregate principal amount of its 1.75% Convertible Senior Notes due 2032 (the “Notes”), including the exercise in full of the underwriters’ option to purchase up to an additional $25.0 million aggregate principal amount of the Notes, solely to cover over-allotments. The Notes were issued pursuant to, and are governed by, an indenture (the “Base Indenture”), dated as of May 11, 2026, between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), as supplemented by a first supplemental indenture (the “Supplemental Indenture,” and the Base Indenture, as supplemented by the Supplemental Indenture, the “Indenture”), dated as of May 11, 2026, between the Company and the Trustee.

Issuer evidence: On May 11, 2026, Viridian Therapeutics, Inc. (the “Company”) completed its public offering (the “Convertible Notes Offering”) of $250,000,000 aggregate principal amount of its 1.75% Convertible Senior Notes due 2032 (the “Notes”), including the exercise in full of the underwriters’ option to purchase up to an additional $25.0 million aggregate principal amount of the Notes, solely to cover over-allotments. The Notes were issued pursuant to, and are governed by, an indenture (the “Base Indenture”), dated as of May 11, 2026, between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), as supplemented by a first supplemental indenture (the “Supplemental Indenture,” and the Base Indenture, as supplemented by the Supplemental Indenture, the “Indenture”), dated as of May 11, 2026, between the Company and the Trustee.

Supporting evidence: The Notes are general, unsecured, senior obligations of the Company. The Notes will accrue interest payable semiannually in arrears on May 15 and November 15 of each year, beginning on November 15, 2026, at a rate equal to 1.75% per year. In addition, special interest will accrue on the Notes upon the occurrence of certain events relating to the Company’s failure to file certain reports with the U.S. Securities and Exchange Commission (the “SEC”) as provided in the Indenture and as described below. The Notes will mature on May 15, 2032 (the “Maturity Date”), unless earlier converted, redeemed or repurchased by the Company.

Supporting evidence: On May 11, 2026, Viridian Therapeutics, Inc. (the “Company”) completed its public offering (the “Convertible Notes Offering”) of $250,000,000 aggregate principal amount of its 1.75% Convertible Senior Notes due 2032 (the “Notes”), including the exercise in full of the underwriters’ option to purchase up to an additional $25.0 million aggregate principal amount of the Notes, solely to cover over-allotments. The Notes were issued pursuant to, and are governed by, an indenture (the “Base Indenture”), dated as of May 11, 2026, between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), as supplemented by a first supplemental indenture (the “Supplemental Indenture,” and the Base Indenture, as supplemented by the Supplemental Indenture, the “Indenture”), dated as of May 11, 2026, between the Company and the Trustee.

Supporting evidence: On May 11, 2026, Viridian Therapeutics, Inc. (the “Company”) completed its public offering (the “Convertible Notes Offering”) of $250,000,000 aggregate principal amount of its 1.75% Convertible Senior Notes due 2032 (the “Notes”), including the exercise in full of the underwriters’ option to purchase up to an additional $25.0 million aggregate principal amount of the Notes, solely to cover over-allotments. The Notes were issued pursuant to, and are governed by, an indenture (the “Base Indenture”), dated as of May 11, 2026, between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), as supplemented by a first supplemental indenture (the “Supplemental Indenture,” and the Base Indenture, as supplemented by the Supplemental Indenture, the “Indenture”), dated as of May 11, 2026, between the Company and the Trustee.